Lorey K. Smith
Melbourne, VIC, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanoma.
Journal: Journal for immunotherapy of cancer
Published: April 28, 2025
The therapeutic potential of targeting minimal residual disease in melanoma.
Journal: Clinical and translational medicine
Published: October 17, 2022
Nuclear stabilization of p53 requires a functional nucleolar surveillance pathway.
Journal: Cell reports
Published: May 19, 2022
Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma.
Journal: Cancers
Published: November 04, 2021
Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies.
Journal: Cancers
Published: October 25, 2021
Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia.
Journal: EMBO molecular medicine
Published: September 23, 2021
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
Journal: Journal for immunotherapy of cancer
Published: August 20, 2021
Is resistance to targeted therapy in cancer inevitable?
Journal: Cancer cell
Published: August 10, 2021
Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death.
Journal: Cancer discovery
Published: April 24, 2021
Last Updated: 09/26/2026